Henry Kranzler, MD
Additional Information & Contact: Dept. of Psychiatry link
Bio
Henry R. Kranzler, M.D. is Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine. His research focuses on the genetics and pharmacological treatment of substance dependence, with a particular emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health. He has authored or co-authored more than 500 journal articles, book chapters, and books, is a member of the editorial board of five peer-review journals, and is the Editor of Alcoholism: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach.
Grants & Funding
- Co-Principal Investigator on Million Veterans Program grant I01 BX003341 01: Genetic Vulnerability for Sustained Multi-Substance Use in MVP.
- National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Ondansetron treatment of alcohol dependence” (R01 AA021164)
- National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Pharmacogenetic analysis of topiramate treatment of AUD” (R01 AA023192)
- National Cancer Institute. Principal Investigator for “Placebo-controlled trial of bupropion for smoking cessation in pregnant women” (R01 CA184315)
Selected Publications
Kranzler HR, Morris PM, Pond T, Crist RC, Kampman KM, Hartwell EE, Lynch KG. Prospective pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology, in press.
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 115:1426-1437, 2020. (PMCID: PMC7340566)
Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, Tate JP, Dao C, Xu K, Polimanti R, Farrer LA, Justice AC, Kranzler HR, Gelernter J, Veterans Affairs Million Veteran Program. Association of OPRM1 functional coding variant with opioid use disorder. A genome-wide association study. JAMA Psychiatry, 2020;77:1072-80. (PMCID: PMC7270886)
Kranzler HR, Zhou H, Kember RL, Smith RV, Justice AC, Damrauer S, Tsao PS, Klarin D, Rader DJ, Regeneron Genetics Center Research Team, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J on behalf of the VA Million Veteran Program. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications, 10:1499, 2019. (PMCID: PMC6445072)
Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction, 114:1547-1555, 2019. (PMCID: PMC6682454)
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen T, Arias AJ, Gelernter J, Oncken C, Pond T, Kampman KM. Topiramate treatment for heavy drinkers: Moderation by a GRIK1 polymorphism, American Journal of Psychiatry, 171: 445-452, 2014. (PMCID: PMC3997125).
Kranzler HR, Armeli, Wetherill R, Feinn R, Tennen H, Gelernter J, Covault J, Pond T. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking. Addiction Biology, 21:450-9, 2016 (PMCID: PMC4468044).
Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, Cook-Sather SD, Kranzler HR, Gelernter J. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Molecular Psychiatry, 22: 346-352, 2017 (PMCID: PMC28115739)
Back to Top